Evidence map›Paper›PMID 38746885›Full record

ArticleACS medicinal chemistry letters2024

Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR.

Nils Pemberton, Nina Compagne, Argyrides Argyrou, Emma Evertsson, Anders Gunnarsson, Jason G Kettle, Jonathan P Orme, Richard A Ward

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nils PembertonMedicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden.ORCID https://orcid.org/0000-0002-8875-7221
Nina CompagneMedicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden.
Argyrides ArgyrouDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.ORCID https://orcid.org/0000-0003-3141-9122
Emma EvertssonMedicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden.
Anders GunnarssonDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden.
Jason G KettleMedicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.ORCID https://orcid.org/0000-0001-7373-0758
Jonathan P OrmeDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
Richard A WardMedicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.ORCID https://orcid.org/0000-0002-2310-9477

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To further facilitate the discovery of cysteine reactive covalent inhibitors, there is a need to develop new reactive groups beyond the traditional acrylamide-type warheads. Herein we describe the design and synthesis of covalent EGFR inhibitors that use vinylpyridine as the reactive group. Structure-based design identified the quinazoline-containing vinylpyridine

Identifiers

PMID38746885
PMCPMC11089552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.